N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
申请人:Lyssikatos Joseph P.
公开号:US08648087B2
公开(公告)日:2014-02-11
This invention provides compounds of Formula I
wherein B, G, A, E, R1, R2, R3, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.
N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
申请人:ARRAY BIOPHARMA, INC.
公开号:US20140023643A1
公开(公告)日:2014-01-23
This invention provides compounds of Formula I
wherein B, G, A, E, R
1
, R
2
, R
3
, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.
N4-Phenyl-Quinazoline-4-Amine Derivatives and Related Compounds as ErbB Type I Receptor Tyrosine Kinase Inhibitors for the Treatment of Hyperproliferative Diseases
申请人:Lyssikatos Joseph P.
公开号:US20110034689A1
公开(公告)日:2011-02-10
This invention provides compounds of Formula I
wherein B, G, A, E, R
1
, R
2
, R
3
, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.
N4-PHENYL-QUINAZOLINE-4 -AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
申请人:Array Biopharma Inc.
公开号:EP1971601A2
公开(公告)日:2008-09-24
N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
申请人:Array BioPharma Inc.
公开号:US20210008023A1
公开(公告)日:2021-01-14
This invention provides compounds of Formula I
wherein B, G, A, E, R
1
, R
3
, R
4
, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.